Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non–small cell lung cancer
Geyun Chang,Weihua Li,Hua Bai,Jianchun Duan,Zhijie Wang,Xinyang Du,Ruofei Yu,Yaxi Wang,Minghao Wang,Yixiang Zhu,Xue Zhang,Li Li,Rui Wan,Jie Wang
DOI: https://doi.org/10.1111/1759-7714.14635
IF: 3.223
2022-09-21
Thoracic Cancer
Abstract:We retrospectively collected data of 1162 non–small cell lung cancer (NSCLC) and analyzed the relationship between the switch/sucrose nonfermentable complex mutations (SWI/SNF‐mut) and clinical outcomes of immune checkpoint inhibitors (ICIs) and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) in advanced NSCLC. The results showed the frequency of SWI/SNF‐mut was 19.8%, of which the most common genetic alterations being (33.4%) and SMARCA4 (28.3%). We found that patients with co‐mutations of SWI/SNF and KRAS had significantly prolonged progression‐free survival (PFS) to ICIs and ARID1A‐mut was associated with improved PFS to EGFR‐TKIs in EGFR‐mutant patients. Our study provides new knowledge on the genetic contributions of SWI/SNF‐mut to efficacy of ICIs and EGFR‐TKIs in advanced NSCLC. Background The switch/sucrose nonfermentable complex mutations (SWI/SNF‐mut) are common in non–small cell lung cancer (NSCLC). However, the association of SWI/SNF‐mut with the clinical outcomes of immune checkpoint inhibitors (ICIs), particularly of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs), has not been established. Methods We retrospectively collected data of patients at Cancer Hospital Chinese Academy of Medical Sciences. Patients with advanced NSCLC who received programmed cell death protein‐1 or programmed cell death ligand 1 (PD‐[L]1) inhibitors were included in cohort 1 and those with EGFR mutations (EGFR‐mutant) received EGFR‐TKIs monotherapy were included in cohort 2. Two reported Memorial Sloan‐Kettering Cancer Center (MSKCC) cohorts received immunotherapy alone used as the validation for cohort 1. We analyzed the relationship between SWI/SNF alterations and clinical outcomes in each cohort. Results In total, 1162 patients were included, of which 230 patients (19.8%) were identified as SWI/SNF‐mut with the most common genetic alterations being ARID1A (33.4%) and SMARCA4 (28.3%). In cohort 1 (n = 146), patients with co‐mutations of SWI/SNF and Kirsten rat sarcoma oncogene (KRAS) (SWI/SNFmutKRASmut, n = 18) had significantly prolonged progression‐free survival (PFS) (8.6 m vs. 1.9 m; hazard ratio [HR], 0.31; 95% confidence intervals [CI], 0.11–0.83; p = 0.032) to PD‐(L)1 inhibitors monotherapy, which was consistent with the MSKCC cohorts (not reach [NR] vs. 6.3 m; HR, 0.36, 95% CI, 0.15–0.82; p = 0.016). In cohort 2 (n = 205), ARID1A‐mut (n = 16) was associated with improved PFS after EGFR‐TKIs (20.6 m vs. 11.2 m; HR, 0.47, 95% CI, 0.27–0.94; p = 0.023). Conclusions In advanced NSCLC, patients with SWI/SNFmutKRASmut seem to benefit more from ICIs. Furthermore, ARID1A‐mut may provide a protective effect to EGFR‐TKIs in EGFR‐mutant patients. However, this is a retrospective single‐institution analysis that requires further validation by large prospective studies.
oncology,respiratory system